2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 788

Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Abstract Number: 789

Direct Coombs Positivity in SLE
Abstract Number: 790

An Intervention to Improve Quality of Life for African-American Lupus Patients
Abstract Number: 791

Impact of Online Education and Social Media Intervetion for Self-Management in Adolescents with SLE
Abstract Number: 792

Incidence and Persistence of Cervical Human Papillomavirus Infection in Mexican Systemic Lupus Erythematosus Women
Abstract Number: 793

Mesenchymal Stem Cells Promote the Generation of CD206+ Macrophage and Increase Its Phagocytic Activity in Systemic Lupus Erythematosus
Abstract Number: 794

CD163+ Macrophages Display Mixed Polarizations in Discoid Lupus Skin
Abstract Number: 795

High Mobility Group Box-1 (HMGB1) Affects Macrophage Polarization and Phagocytosis in Systemic Lupus Erythematosus Patients
Abstract Number: 796

Single Cell Gene Expression Studies in Lupus Patient Monocytes Reveal a Unique Anti-Inflammatory Population of Non-Classical Monocytes Associated with Clinical Quiescence
Abstract Number: 797

Divergent Phenotypic Patterns Between Systemic Lupus Erythematosus and Healthy Anti-Nuclear Antibody Positive Individuals Reveal Distinct Differences in B Cell and Myeloid Populations Among Ethnicities
Abstract Number: 798

Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin
Abstract Number: 799

Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes
Abstract Number: 800

A High-Throughput System for Quantification of in Vitro Neutrophil Extracellular Trap Formation with Fluorescence Immunocytochemistry
Abstract Number: 801

Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1
Abstract Number: 802

Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].